Bicara Therapeutics
Tracked across 11 events · 134 articles · First seen May 05, 2026 · Last active Aug 19, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Bicara Therapeutics secured $180 million in financing to advance its lead drug candidate, deupirfenidone, for idiopathic pulmonary fibrosis, enabling the initiation of a crucial Phase 3 trial.
Jul 02, 2026 · 6 articles
Business
Bicara Therapeutics, an AI-driven drug discovery company based in Chengdu, China, announced the successful closing of an oversubscribed Series A financing round, raising nearly $30 million. The round was co-led by Legend Holdings and Shanghai…
Impact: Bicara Therapeutics is the central entity, successfully closing an oversubscribed Series A financing round of nearly $30 million. This funding will accelerate its AI-driven drug discovery platform and pipeline development, enhancing its competitive position and growth prospects.
Jul 20, 2026 · 6 articles
Business
On August 19, 2026, BioArctic and Bicara Therapeutics announced a research collaboration agreement to develop a novel antibody-based treatment for glioblastoma, an aggressive brain cancer. The collaboration combines BioArctic's BrainTransporter technology with Mesenkia's KITAIbodies platform,…
Impact: Mesenkia is a key party, providing its KITAIbodies platform and antibody targeting HVEM. The collaboration validates its technology and provides resources to advance its glioblastoma program.
Aug 19, 2026 · 6 articles
Business
Impact: Kaveri receives exclusive rights to two promising oncology programs and seed funding, positioning it to advance clinical trials and raise additional capital.
Jul 21, 2026 · 7 articles
Business
Impact: Bicara Therapeutics, a Nasdaq-listed firm incubated by Biocon, is led by Claire Mazumdar and has seen its market capitalization exceed $1.6 billion under her leadership.
May 05, 2026 · 40 articles
Regulatory
Monteverde & Associates PC, a securities class action firm, has launched and continued investigations into numerous proposed mergers and acquisitions on behalf of shareholders. The firm is examining the terms of transactions involving companies such…
Impact: Acquirer in the Rallybio merger; subject to investigation.
Jul 20, 2026 · 20 articles
Business
Impact: Bicara Therapeutics is the current employer of Vicky Papoutsis, but the event does not directly affect the company.
Jul 30, 2026 · 6 articles
Business
Impact: Bicara Therapeutics is mentioned as a co-development partner for Insilico's CNS program, but is not directly involved in this event.
Jul 13, 2026 · 6 articles
Business
Impact: Bicara Therapeutics was acquired by Eli Lilly earlier in 2026, a genetic-medicine biotechnology company.
Jul 16, 2026 · 25 articles
Business
Cocrystal Pharma, Inc., a clinical-stage biotechnology company developing antiviral therapeutics, announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings decades of experience in antiviral therapy,…
Impact: Bicara Therapeutics is mentioned as a company where Brosgart previously held a board position and where she worked with CEO Sapirstein; no direct impact.
Aug 17, 2026 · 6 articles
100
Bicara Therapeutics completed financing roundBeyang Therapeutics closes...
90
Legend Holdings co-led financing round Bicara TherapeuticsBeyang Therapeutics closes...
90
Shanghai Healthcare Capital co-led financing round Bicara TherapeuticsBeyang Therapeutics closes...
90
BioArctic signed research collaboration Bicara TherapeuticsBioArctic Mesenkia...
70
Inspire Medical Systems participated in financing Bicara TherapeuticsBeyang Therapeutics closes...
70
Fenglei Capital participated in financing Bicara TherapeuticsBeyang Therapeutics closes...
70
Shanghai Sci-Tech Innovation Center Capital participated in financing Bicara TherapeuticsBeyang Therapeutics closes...
70
Harbor & Canton Capital participated in financing Bicara TherapeuticsBeyang Therapeutics closes...
60
Root Venture Partners continued support Bicara TherapeuticsBeyang Therapeutics closes...
60
YuanBio Venture Capital continued support Bicara TherapeuticsBeyang Therapeutics closes...
ERGEN INTELLIGENCE
Track Bicara Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard